secures FDA nod for echocardiography AI software

By staff writers

September 14, 2021 -- Artificial intelligence (AI) software developer has secured U.S. Food and Drug Administration (FDA) clearance for its Us2.v1 echocardiography image analysis software.

Designed to serve as a decision-support tool for cardiologists and primary care physicians, the software application analyzes both 2D and cardiac Doppler ultrasound images and automatically measures 23 echocardiography parameters, according to the vendor. It then creates a fully automated patient report with editable annotations, conclusions, and comparisons with international reference guidelines, the company said.

The software's performance has been assessed in an external validation study performed at Brigham and Women's Hospital. It's now available in the U.S.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking